文献速递心境障碍

靶向元可塑性机制以促进持续抗抑郁效应

Targeting metaplasticity mechanisms to promote sustained antidepressant actions.
PubMed 文献 · Mol Psychiatry · 2024-01-04

本文综述了亚麻醉剂量氯胺酮及艾司氯胺酮在难治性抑郁患者中快速起效且停药后疗效持续的现象,提出元可塑性(metaplasticity)机制可能是下一代抗抑郁药的关键靶点。多种快速起效抗抑郁药虽起始机制不同,但下游分子介导的突触可塑性增强效应趋同,靶向元可塑性机制有望减少给药频率并降低不良反应。

要点

  • 氯胺酮/艾司氯胺酮快速抗抑郁且停药后疗效持续,推动抑郁症治疗概念转变
  • 抑郁病理生理涉及情绪调节环路兴奋性谷氨酸能突触受损
  • 元可塑性通过启动神经元改变后续可塑性反应,可能成为可成药靶点

核心结论

  • 靶向元可塑性机制可增强兴奋性神经传递和突触可塑性能力,促进持续抗抑郁效应。
  • 多种快速起效抗抑郁药的起始机制不同但下游分子介导趋同,元可塑性过程可作为下一代治疗的可成药靶点。

研究设计与样本

  • 本文为综述,汇总药理学多样化的快速起效抗抑郁药(氯胺酮模拟物)的起始与持续机制证据。

主要发现

  • 亚麻醉剂量氯胺酮和艾司氯胺酮在难治性抑郁患者中快速诱导抗抑郁效应,并在药物清除后促进持续效应。
  • 快速起效抗抑郁药的起始机制可不同(如细胞类型特异性、NMDAR亚型选择性抑制与激活、mGluR2/3拮抗、AMPA受体增强、5-HT受体激活致幻剂等)。
  • 持续治疗机制部分由元可塑性效应介导,趋同于一致的分子介导物以增强兴奋性神经传递和改变突触可塑性能力。

临床怎么用

  • 靶向元可塑性机制可能减少给药频率及相关不良反应,因无需药物持续存在。
  • 下一代抗抑郁药开发可考虑以元可塑性过程为靶点,增强谷氨酸能突触可塑性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The discovery that subanesthetic doses of (R, S)-ketamine (ketamine) and (S)-ketamine (esketamine) rapidly induce antidepressant effects and promote sustained actions following drug clearance in depressed patients who are treatment-resistant to other therapies has resulted in a paradigm shift in the conceptualization of how rapidly and effectively depression can be treated. Consequently, the mechanism(s) that next generation antidepressants may engage to improve pathophysiology and resultant symptomology are being reconceptualized. Impaired excitatory glutamatergic synapses in mood-regulating circuits are likely a substantial contributor to the pathophysiology of depression. Metaplasticity is the process of regulating future capacity for plasticity by priming neurons with a stimulation that alters later neuronal plasticity responses. Accordingly, the development of treatment modalities that specifically modulate the duration, direction, or magnitude of glutamatergic synaptic plasticity events such as long-term potentiation (LTP), defined here as metaplastogens, may be an effective approach to reverse the pathophysiology underlying depression and improve depression symptoms. We review evidence that the initiating mechanisms of pharmacologically diverse rapid-acting antidepressants (i.e., ketamine mimetics) converge on consistent downstream molecular mediators that facilitate the expression/maintenance of increased synaptic strength and resultant persisting antidepressant effects. Specifically, while the initiating mechanisms of these therapies may differ (e.g., cell type-specificity, N-methyl-D-aspartate receptor (NMDAR) subtype-selective inhibition vs activation, metabotropic glutamate receptor 2/3 antagonism, AMPA receptor potentiation, 5-HT receptor-activating psychedelics, etc.), the sustained therapeutic mechanisms of putative rapid-acting antidepressants will be mediated, in part, by metaplastic effects that converge on consistent molecular mediators to enhance excitatory neurotransmission and altered capacity for synaptic plasticity. We conclude that the convergence of these therapeutic mechanisms provides the opportunity for metaplasticity processes to be harnessed as a druggable plasticity mechanism by next-generation therapeutics. Further, targeting metaplastic mechanisms presents therapeutic advantages including decreased dosing frequency and associated diminished adverse responses by eliminating the requirement for the drug to be continuously present.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Brown KA, Gould TD. Targeting metaplasticity mechanisms to promote sustained antidepressant actions. Mol Psychiatry. 2024. PMID: 38177353. doi:10.1038/s41380-023-02397-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。